Bad news for neuroprotective therapies in PD?

Journal of Parkinson's Disease

Volumn 3, Issue 3, 2013, Pages 271-273

  Cenci, M Angela ^a   Brooks, David J ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE;

CLINICAL FEATURE; DOPAMINERGIC NERVE CELL; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; NONHUMAN; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA PARS COMPACTA; SYMPTOM ASSESSMENT;

DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84888878446     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-139001     Document Type: Note

References (27)

1. Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, & Ben-Shlomo Y, et al. (2013) Parkinson's disease-The debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis, 3(1), 1-11
2. Morrish PK, Sawle GV, & Brooks DJ (1996) An [18F]dopa-PETand clinical study of the rate of progression in Parkinson's disease. Brain, 119(Pt 2), 585-591
3. Marsden CD (1990) Parkinson's disease. Lancet, 335(8695), 948-952
4. Fearnley JM, & Lees AJ (1991) Ageing Parkinson's disease: Substantia nigra regional selectivity. Brain, 114(Pt 5), 2283-2301
5. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, et al. (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol, 184(Suppl 1), S68-79
6. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, & Sager H, et al. (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol, 47(12), 1290-1298
7. Varrone A, Marek KL, Jennings D, Innis RB, & Seibyl JP (2001) [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.Mov Disord, 16(6), 1023-1032
8. Cenci MA, Ohlin KE, & Odin P (2011) Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets, 10(6), 670-684
9. Okereke CS (2002) Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa. J Pharm Pharm Sci, 5(2), 146-61
10. Cenci MA, & Lundblad M (2006) Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem, 99(2), 381-392
11. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, & Adler CH, et al. (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 136(Pt 8), 2419-2431
12. Kish SJ, Shannak K, & Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med, 318(14), 876-880
13. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, & Rinne JO (2006) Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease:Atwo-year follow-up study.Mov Disord, 21(7), 958-963
14. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R,&Rinne JO (2009) A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen Mov Disord, 24(7), 1009-1015
15. Marek K, Innis R, van Dyck C, Fussell B, Early M, & Eberly S, et al. (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology, 57(11), 2089-2094
16. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, &Sonninen P, et al. (2001) Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study. Mov Disord, 16(4), 608-615
17. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, & Penn R, et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol, 59(3), 459-466
18. Patel NK, Pavese N, Javed S, Hotton GR, Brooks DJ, Gill SS (2013) Benefits of putaminal gdnf infusion in parkinson disease are maintained after gdnf cessation. Neurology
19. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, & Gill SS (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med, 11(7), 703-704
20. Georgievska B, Kirik D, Rosenblad C, Lundberg C, & Bjorklund A (2002) Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport, 13(1), 75-82
21. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y,&Leventhal L, et al. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 290(5492), 767-773
22. Lindgren N, Francardo V, Quintino L, Lundberg C, & Cenci MA (2012) AModel of GDNF Gene Therapy inMice with 6-Hydroxydopamine Lesions: Time Course of Neurorestorative Effects and ERK1/2 Activation. J Parkinsons Dis, 2(4), 333-348
23. O'Keeffe GC, Tyers P, Aarsland D, Dalley JW, Barker RA, & Caldwell MA (2009) Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A, 106(21), 8754-8759
24. Paul G, Ozen I, Christophersen NS, Reinbothe T, Bengzon J, & Visse E, et al. (2012) The adult human brain harbors multipotent perivascular mesenchymal stem cells. PLoS One, 7(4), e35577
25. van den Berge SA, van Strien ME, Korecka JA, Dijkstra AA, Sluijs JA, & Kooijman L, et al. (2011) The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain. Brain, 134(Pt 11), 3249-3263
26. Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, & Piccini P, et al. (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov, 10(5), 377-393
27. Laviola G, Hannan AJ, Macri S, Solinas M,&Jaber M (2008) Effects of enriched environment on animal models of neurodegenerative diseases and psychiatric disorders. Neurobiol Dis, 31(2), 159-168